Description General description A cell-permeable, potent, selective, competitive, and reversible inhibitor of CD45 (IC50 = 200 nM or 3.8 µM using pNPP or phosphorylated Ick505 peptide as a substrate, respectively). Does not effectively inhibit PTPIB (IC50 >30 µM using phosphorylated Ick505 peptide as a substrate). The phenanthrenedione group does not function as a thiol oxidizing agent. One of the most potent inhibitor of phosphatase tensin homolog deleted on chromosome 10 (PTEN) that enhances PIP3 signaling in a variety of cells and improves the efficacy of granulocyte transfusion in murine models of neutropenia-related pneumonia. A cell-permeable, potent, selective, competitive, and reversible inhibitor of CD45 (IC50 = 200 nM using pNPP as the substrate, 3.8 µM for CD45 lck, >30 µM for PTP1B lck) that displays anti-proliferative properties. Also reported to potently block T-cell receptor-mediated proliferation (IC50 = 100 nM). Shown to be less cytotoxic (CC50 = 3.5 µM) than other 1,2-naphthalenedione analogs. The phenanthrenedione group does not function as a thiol oxidizing agent. One of the most potent inhibitor of phosphatase tensin homolog deleted on chromosome 10 (PTEN) that enhances PIP3 signaling in a variety of cells and improves the efficacy of granulocyte transfusion in murine models of neutropenia-related pneumonia. Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target CD45 using pNPP as a substrate Product does not compete with ATP. Reversible: yes Target IC50: 200 nM or 3.8 µM against CD45 using pNPP or phosphorylated Ick505 peptide as a substrate, respectively Packaging Packaged under inert gas Warning Toxicity: Harmful (C) Other Notes Li, Y., et al. 2011. Blood117, 6702. Urbanek, R.A., et al. 2001. J. Med. Chem.44, 1777.